subscribeSubscribe
Vincerx Announces Compelling Efficacy of Enitociclib with Venetoclax

Vincerx Announces Compelling Efficacy of Enitociclib with Venetoclax
GLOBENEWSWIRE
07 Jan 2024
Share Share
FDA approves J&J`s PARP combo drug Akeega for prostate cancer

FDA approves J&J`s PARP combo drug Akeega for prostate cancer
FDA
12 Aug 2023
Share Share
Health Canada approves Lynparza with abiraterone for patients with BRCA mCRPC

Health Canada approves Lynparza with abiraterone for patients with BRCA mCRPC
BIOSPACE
14 Jul 2023
Share Share
Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated FL, MZL

Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated FL, MZL
Caroline Seymour ONCLIVE
20 Jun 2023
Share Share
US FDA panel backs restricted use of AstraZeneca`s prostate cancer drug

US FDA panel backs restricted use of AstraZeneca`s prostate cancer drug
BUSINESS-STANDARD
02 May 2023
Share Share
Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib)

Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib)
BUSINESSWIRE
28 Apr 2023
Share Share
MHRA approves prostate cancer combination therapy

MHRA approves prostate cancer combination therapy
EUROPEAN PHARMACEUTICAL REVIEW
21 Mar 2023
Share Share
Lynparza`s final OS results come up short in PROpel study

Lynparza`s final OS results come up short in PROpel study
PRESS RELEASE
17 Feb 2023
Share Share
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
GLOBENEWSWIRE
16 Feb 2023
Share Share
LYNPARZA With Abiraterone and Prednisone Approved in the EU for mCRPC

LYNPARZA With Abiraterone and Prednisone Approved in the EU for mCRPC
PRESS RELEASE
21 Dec 2022
Share Share